Cardiovasculaire Geneeskunde.nl

New frontiers in managing the RAS & renin inhibition

Slides (presentatie) - Nov. 8, 2011

New frontiers in managing the RAS & renin inhibition: Where are we now?


Prof. Wiek van Gilst – Clinical Pharmacologist
University Medical Center Groningen, The Netherlands

 


Bekijk of download de presentatie

klik voor bekijken op onderstaande afbeeldingen





Cardiovascular Exchange Summit 2011

Major clinical outcome trials of RAAS manipulation

Where are we now?

Angiotensin-receptor blockade and risk of cancer

ARB and cancer occurrence

ARB and cancer deaths

Antihypertensive drugs and risk of cancer

Network meta-analyses

ARBs and cancer risk

Use of Angiotensin Receptor Blockers and the Risk of Cancer

EMA opinion ARBs

Where are we now?

Elevated plasma renin activity is associated with increased risk of MI

VAL-HeFT trial

Prognostic value of renin

Prorenin and Heart Failure



Cardiospecific overexpression of (P)RR

Isoprenalin

Prorenin, Renin, and Their Receptor

Renin- and prorenin-induced effects

(Pro)Renin receptor

Where are we now?

Aliskiren

ASPIRE

ASPIRE

ASPIRE

ASPIRE

Progression of left ventricular dysfunction

SAVE—Results of the Survival and Ventricular Enlargement Trial

All-Cause Mortality

Effect of captopril

The SAVE Study

Meta-analysis of Remodeling Trials

Absence of CHF in patients after AMI

Ventricular dilatation and infarct size

ASPIRE

Conclusions

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: